- Market Capitalization, $K 1,239,185
- Shares Outstanding, K 286,186
- Annual Sales, $ 179,280 K
- Annual Income, $ -12,470 K
- 60-Month Beta 2.19
- Price/Sales 3.16
- Price/Cash Flow N/A
- Price/Book 0.83
|Period||Period Low||Period High||Performance|
| || |
-0.67 (-13.45%)since 06/08/20
| || |
+1.12 (+35.11%)since 04/08/20
| || |
-2.44 (-36.15%)since 07/08/19
Global Medical Marijuana Market Size research report with COVID-19 impact is considered to be an extremely intelligent and deep assessment of the present industrial conditions along with the overall Medical...
LEAMINGTON, ON, /PRNewswire/ - Aphria Inc. ("") (TSX: APHA and NASDAQ: APHA), a leading global cannabis company, today announced that it has issued 1,658,375 common shares (the "") to Emblem Cannabis...
, /PRNewswire/ -- The political push for the legalization of psychedelic products is now underway. Earlier this week, an ballot measure to legalize the use of psilocybin, a naturally occurring psychedelic...
The report offers a comprehensive overview of the current market scenario, competitive landscape with detailed profiles of key companies, leading regions, product types, applications, and end industries....
Aphria Inc. (APHA) closed the most recent trading day at $4.29, making no change from the previous trading session.
According to a newly published report by , ““. The prime objective of the report is to deliver a Ten-year (2020-2029) market forecast. The latest study focusing on medical cannabis market with topmost...
, /PRNewswire/ -- The global health crisis has actually increased the sales of cannabis-infused products. New reports reveal cannabis consumers in are becoming more interested in cannabis-infused products....
, /PRNewswire/ - Aphria Inc. ("") (TSX: APHA and NASDAQ: APHA), a leading global cannabis company, Emblem Cannabis Corporation (""), and Aleafia Health Inc. (TSX: AH, OTC: ALEAF) ("") today announced...
The pandemic situation across the globe is predicted to have a negative impact on the market. The market is predicted to recover by Q3/Q4 2022. The major vaccine manufacturer are focusing more on developing...